Moberg Pharma AB (publ) (STO:MOB)
Sweden · Delayed Price · Currency is SEK 9.33
-0.04 (-0.43%)
Jul 24, 2026, 5:19 PM CET
Moberg Pharma AB Income Statement
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 14.59 | 13.54 | 9.81 | - | 0.21 | - | |
Revenue Growth (YoY) | 13.47% | 37.99% | - | - | - | - |
Cost of Revenue | 6.22 | 5.86 | 3.5 | - | - | - |
Gross Profit | 8.37 | 7.68 | 6.32 | - | 0.21 | - |
Selling, General & Admin | 31.45 | 32.14 | 28.97 | 24.86 | 21.07 | 18.51 |
Research & Development | 4.56 | 3.54 | 302.23 | 3.66 | 1.18 | 3.45 |
Other Operating Expenses | -2.59 | -0.68 | -0.06 | -1.05 | -1.82 | -2.23 |
Total Operating Expenses | 33.42 | 35 | 331.15 | 27.46 | 20.43 | 19.73 |
Operating Income | -25.04 | -27.32 | -324.83 | -27.46 | -20.23 | -19.73 |
Interest Income | 3.14 | 3.48 | 4.58 | 2.3 | 0.79 | - |
Interest Expense | -0.16 | -0.18 | -0.23 | -0.26 | -0.07 | -0.24 |
Total Non-Operating Income (Expense) | 2.98 | 3.3 | 4.36 | 2.04 | 0.71 | -0.24 |
Pretax Income | -22.06 | -24.02 | -320.47 | -25.42 | -19.51 | -19.97 |
Provision for Income Taxes | -3.67 | -3.22 | 65.36 | 4.33 | - | 3.75 |
Net Income | -18.39 | -20.8 | -385.84 | -29.75 | -19.51 | -23.72 |
Minority Interest in Earnings | - | - | - | - | - | -0.13 |
Earnings From Discontinued Operations | - | - | - | - | - | 23.59 |
Net Income to Common | -25.73 | -20.8 | -385.84 | -21.09 | -15.71 | 7.49 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 47 | 47 | 38 | 16 | 8 | 4 |
Shares Outstanding (Diluted) | 47 | 48 | 39 | 36 | 8 | 4 |
Shares Change (YoY) | 7.18% | 23.91% | 9.54% | 358.20% | 75.65% | 131.75% |
EPS (Basic) | -0.55 | -0.58 | -6.74 | -1.33 | -2.07 | 1.70 |
EPS (Diluted) | -0.55 | -0.58 | -6.74 | -1.33 | -2.07 | 1.70 |
EPS Growth | - | - | - | - | - | - |
Free Cash Flow | -12.23 | -17.49 | -16.47 | -33.21 | -16.84 | -15.3 |
Free Cash Flow Growth | - | - | - | - | - | - |
Free Cash Flow Per Share | -0.26 | -0.36 | -0.42 | -0.93 | -2.17 | -3.47 |
Gross Margin | 57.38% | 56.73% | 64.37% | - | 100.00% | - |
Operating Margin | -171.63% | -201.77% | -3310.88% | - | -9771.01% | - |
Profit Margin | -126.04% | -153.64% | -3932.70% | - | -9426.09% | - |
FCF Margin | -83.82% | -129.18% | -167.87% | - | -8136.23% | - |
EBITDA | -24.24 | -25.71 | -23.51 | -25.36 | -17.64 | -17.15 |
EBITDA Margin | -166.11% | -189.89% | -239.64% | - | -8523.67% | - |
EBIT | -25.04 | -27.32 | -324.83 | -27.46 | -20.23 | -19.73 |
EBIT Margin | -171.63% | -201.77% | -3310.88% | - | -9771.01% | - |
Effective Tax Rate | 16.63% | 13.40% | -20.40% | -17.02% | 0.00% | -18.77% |